CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration of other innovative products. While the financial details of the agreement were not disclosed, this partnership signifies a significant step in the global expansion of CanSino Biologics’ research and development efforts.- Flcube.com
Recent news:
-
BRL Medicine Inc. Secures Nearly $30 Million in B+ Round Financing to Advance Pipeline -
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies -
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC -
First Patient Dosed in Abbisko's Phase II Trial of ABSK061 and ABSK043 in FGFR2/3 Altered Tumors -
Bayer's Nubeqa Files for FDA Approval in mHSPC
